This profile was last updated on . .
Is this you? Claim your profile.
Executive Advisory Board Member
Synopsis: April 2000
Barry Freehill, also a community member, presented a concept sheet at the March SAC/CAB for a randomized, controlled trial to determine if continuing 3TC when switching to a new HAART regimen in patients with the M184V mutation is associated with a slower rate of development of resistance and virologic failure as compared to not continuing 3TC when switching to a new HAART regimen.
Common Wealth Development Inc
Compass Group PLC
OSF Saint Anthony Medical Center
NXP Semiconductors N.V